The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.
about
Nonhuman primate models for HIV/AIDS vaccine developmentAntiretroviral therapy for prevention of HIV transmission: implications for EuropeA Small Molecule, Which Competes with MAdCAM-1, Activates Integrin α4β7 and Fails to Prevent Mucosal Transmission of SHIV-SF162P3A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex VivoVaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsBottlenecks in HIV-1 transmission: insights from the study of founder virusesPolymorphisms in the α4 integrin of neotropical primates: insights for binding of natural ligands and HIV-1 gp120 to the human α4β7Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder VirusCellular superspreaders: an epidemiological perspective on HIV infection inside the bodyImmune-correlates analysis of an HIV-1 vaccine efficacy trialRecent Insights into the HIV/AIDS Pandemic.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentHSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target.Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.Generation and characterization of an HIV-1 subtype C transmitted and early founder virus consensus sequence.The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.Phenotypic properties of transmitted founder HIV-1Blocking of integrins inhibits HIV-1 infection of human cervical mucosa immune cells with free and complement-opsonized virions.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trialCharacterization of HIV-1 envelopes in acutely and chronically infected injection drug usersTargeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection.Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.Models for predicting effective HIV chemoprevention in womenCharacterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry.Role of donor genital tract HIV-1 diversity in the transmission bottleneck.Viral determinants of HIV-1 macrophage tropism.South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α ResistanceIntegrin α4β7 Expression Increases HIV Susceptibility in Activated Cervical CD4+ T Cells by an HIV Attachment-Independent Mechanism.Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchAssociation of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity.Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.The HIV-1 envelope protein gp120 is captured and displayed for B cell recognition by SIGN-R1(+) lymph node macrophages.
P2860
Q26861148-B9AA0454-B264-4C7E-BF39-EE50B34044C0Q27023464-8FD7A889-686F-4F39-885C-BBB01F7EE31EQ27313287-7DF9D40A-2530-453C-94C0-A1BF6BEF92F5Q27334384-56B516E0-C89C-4D3D-91D1-AFDAA22B0DB1Q27675879-992C620B-73A3-4F0D-B40E-5ACC58B97A48Q27677941-1013276C-4340-48F1-AA35-413AAA235911Q28082862-B66D67DD-A9AA-4056-9B18-01DAFB4414AAQ28476793-D71052D0-8B6C-4FFE-8F3E-7DA7CB21E1E6Q28551914-06C15939-BA8E-4B48-B808-F6266A7FA312Q28657772-3D46F448-9E6B-47A3-AF87-5B99015A01C9Q29617377-189731B7-B18C-4D86-B818-5FDDD87928FEQ30235024-99BB98B7-4572-40EC-B52F-586786042A46Q30355260-4575F9C0-7492-429D-B1E7-C4AF267F2411Q33954386-B0914057-A6BE-441C-93A6-1BF28225A682Q34059103-2B295EDA-2009-4D11-AA5A-AD79254C1194Q34266252-96F673FF-0FE2-49E7-97EB-326EB6FEB243Q34303849-DD4F6C6B-56CF-4433-BAC3-6774D50D1449Q34336058-574B5DCB-890A-4880-A8D2-E721F90345C7Q34507239-61F815E6-2833-4B59-90B4-FB6F28CEC821Q34555891-BBAE6AEE-8EC7-42DF-AF3C-CF6F629BDEDCQ34562259-6BFA66FF-A29D-48AB-B6A0-C0665ABB8CBDQ34620235-EBCA136F-BFD6-43F2-8749-8656758B4877Q34641933-D5F88C68-ADEE-4F77-910D-9197E27538D8Q34907398-72B21948-15C1-46FB-A2D2-F1206E0EDF78Q35060140-A463CD55-7F37-4D74-A8EF-4C0D719511FEQ35061529-6B9DDBB6-06B9-469B-A62E-BD74ED8AE202Q35102285-92139D1C-E060-4A36-8A16-481CF445A40FQ35140429-5B779413-EFB9-4F47-88AD-434861E794AAQ35558621-32446D75-1BAB-4F97-BEC2-58010001F88CQ35593158-CD0F45B2-C7F3-4536-A8DE-CB23DD2B0D5DQ35672336-9349A5C3-D7DA-4D0C-A8EC-E5483A5CE5D1Q35778333-8DBC7614-6BD6-450D-BE27-CF8B465B8164Q35855028-D925660B-04FE-4C82-8934-9FB7D90B5B89Q35857404-EC405E74-35C9-4699-9F7A-E8B591802A92Q35861256-6E3B75D3-C2DD-4CB1-AD8C-524151767DE1Q35956940-D3E5B052-6A27-46C4-B381-0943C132CA98Q36000722-D92AF839-0ACD-4967-A745-8EAD0C98AD2CQ36046570-E166E3D9-0B0B-41F6-8B0B-37C1709AB9ADQ36060423-4E99A049-9C9D-4E45-BB37-6C8E9FF082E4Q36071444-7B81171D-6DFA-489B-A2AA-60A4207D0CB4
P2860
The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The genotype of early-transmit ...... rgets in mucosal transmission.
@ast
The genotype of early-transmit ...... rgets in mucosal transmission.
@en
type
label
The genotype of early-transmit ...... rgets in mucosal transmission.
@ast
The genotype of early-transmit ...... rgets in mucosal transmission.
@en
prefLabel
The genotype of early-transmit ...... rgets in mucosal transmission.
@ast
The genotype of early-transmit ...... rgets in mucosal transmission.
@en
P2093
P2860
P1433
P1476
The genotype of early-transmit ...... rgets in mucosal transmission.
@en
P2093
Danlan Wei
Donald Van Ryk
Fatima Nawaz
James Arthos
Jonathan P McNally
Katharine E Block
Katija Jelicic
Massimiliano Pascuccio
Nikita Patel
Olajumoke Ogundare
P2860
P304
P356
10.1371/JOURNAL.PPAT.1001301
P577
2011-02-24T00:00:00Z